PIF: “Pharmaceutical Innovation Under Intense Pressure”
The highest clawback in the EU, the suspension of innovative cancer therapies, the increasing delays in the arrival of new treatments, and disinvestment in innovation create a worrying environment that requires shared responsibility and immediate action. PhARMA Innovation Forum (PIF), representing 30 leading biopharmaceutical companies engaged in the research, development, and provision of innovative therapies,…
